Skip to main content
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
As of Mar 26
Science1 sourcesNeutral

PKU ballyhoo averting Street’s gaze from Maze phase II AMKD win?

Maze Therapeutics Inc. continues its journey toward a pivotal program after sharing positive top-line data from the phase II Horizon study with MZE-829, an oral, small-molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease (AMKD).

RO
randy osborne
via Bioworld
ShareRead original

Read the full article at Bioworld →

PKU ballyhoo averting Street’s gaze from Maze phase II AMKD win?

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Bioworld
Bioworld
NewsData

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
World Food Prize goes to food safety scientist for preventing millions of cases of foodborne illness
Next
Male Hormones Linked to Aggressive Rare Pediatric Brain Tumor

Related Articles

Extreme global climate outcomes are possible even at 2°C warming, study warnsScience
Extreme global climate outcomes are possible even at 2°C warming, study warns
Phys.org-13h ago-1 sources
Corcept’s Lifyorli wins early FDA approval for ovarian cancerScience
Corcept’s Lifyorli wins early FDA approval for ovarian cancer
Bioworld-13h ago-1 sources
Merck adds Terns’ promising CML drug in $6.7B buyoutScience
Merck adds Terns’ promising CML drug in $6.7B buyout
Bioworld-13h ago-1 sources